The FDA has approved the first-ever mRNA-based seasonal flu vaccine for adults 50 and older, leveraging the same groundbreaking technology used in COVID-19 shots to fight influenza. Moderna's mFLUSIVA cleared the regulatory hurdle on August 5, marking a significant milestone in vaccine technology adaptation.

Vital Signs

Key numbers from this week's FDA actions:

• 40,703: Participants in the clinical trial comparing mFLUSIVA to standard flu vaccine
• 26.6%:...